Association of spermidine plasma levels with brain aging in a population-based study

Introduction Supplementation with spermidine may support healthy aging, but elevated spermidine tissue levels were shown to be an indicator of Alzheimer's disease (AD). Methods Data from 659 participants (age range: 21-81 years) of the population-based Study of Health in Pomerania TREND were included. We investigated the association between spermidine plasma levels and markers of brain aging (hippocampal volume, AD score, global cortical thickness [CT], and white matter hyperintensities [WMH]). Results Higher spermidine levels were significantly associated with lower hippocampal volume (ss = -0.076; 95% confidence interval [CI]: -0.13 to -0.02; q = 0.026), higher AD score (ss = 0.118; 95% CI: 0.05 to 0.19; q = 0.006), lower global CT (ss = -0.104; 95% CI: -0.17 to -0.04; q = 0.014), but not WMH volume. Sensitivity analysis revealed no substantial changes after excluding participants with cancer, depression, or hemolysis. Discussion Elevated spermidine plasma levels are associated with advanced brain aging and might serve as potential early biomarker for AD and vascular brain pathology.

Automated summary

This study found that elevated spermidine levels are associated with Alzheimer's disease and vascular brain pathology, suggesting that spermidine may serve as an early biomarker. Higher levels of spermidine were correlated with smaller hippocampal volume, higher AD score, and lower global cortical thickness.